This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Ganciclovir

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Indications:-

  • life or sight-threatening cytomegalovirus infections in immunocompromised patients only. NOT FOR NEONATAL OR CONGENITAL CYTOMEGALOVIRUS INFECTION

Cautions:

  • history of exposure to radiation or to drugs toxic to bone marrow
  • increased risk of seizures with imipenem
  • potential carcinogen
  • haematological toxicity
  • renal impairment
  • concomitant administration of drugs that prevent replication of rapidly dividing cells
  • ensure adequate hydration
  • vesicant - infuse only into veins with adequate blood flow

Contra-indications:

  • pregnancy and breast feeding
  • hypersensitivity to ganciclovir or acyclovir
  • abnormally low neutrophil counts

Side-effects:

  • neutropenia and thrombocytopenia
  • anaemia and eosinophilia
  • fever
  • rash
  • abnormal liver function tests
  • raised blood urea nitrogen or serum creatinine
  • sepsis
  • facial oedema
  • sore throat
  • epistaxis
  • malaise
  • others - See current issue of BNF

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.